Beam Therapeutics Inc. (BEAM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?
Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy
Beam Therapeutics (BEAM) Gene editing firm Beam Therapeutics is developing its own pipeline with base editing as its foundation technology, a technique that changes a single DNA or RNA base without cutting the DNA strand.
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19.
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024. ESCAPE technology, looking to provide non-genotoxic conditioning for HSCT patients, is to be presented at the upcoming ASH 2024 Annual Meeting. The global Sickle Cell Disease treatment market size is projected to grow to $9.84 billion by 2030.
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications John Evans - Chief Executive Officer Giuseppe Ciaramella - President Amy Simon - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dae Gon Ha - Stifel Eric Joseph - JPMorgan Kostas Biliouris - BMO Capital Markets Samantha Semenkow - Citi Sami Corwin - William Blair Luca Issi - RBC Capital Michael Yee - Jefferies Rick Bienkowski - Cantor Fitzgerald Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Beam Therapeutics Conference Call. At this time, all participants are in a listen-only mode.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago.
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
